Abstract
Cardiovascular disease is one of the most important risk factors for mortality and morbidity in patients with Chronic Kidney Disease (CKD). This systematic review focuses on the protective effects of diuretics against the development of cardiovascular disease in patients with CKD. Among various kinds of diuretics, spironolactone, a mineralocorticoid receptor antagonist, has been shown to have protective effects against cardiovascular disease in patients with all stages of CKD, including predialysis, hemodialysis, and peritoneal dialysis. Low-dose loop diuretics have also been shown to have cardioprotective effects in patients with CKD during the pre-dialysis and hemodialysis stages; however, high-dose loop diuretics have failed to show these cardioprotective effects. The protective effects of other classes of diuretics, including thiazide and tolvaptan, against cardiovascular diseases in patients with CKD remain unclear.
Keywords: Diuretics, cardiovascular disease, chronic kidney disease, spironolactone, mineralocorticoid receptor antagonist, dialysis.
Graphical Abstract
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review
Volume: 16 Issue: 1
Author(s): Akinori Aomatsu, Susumu Ookawara, Kenichi Ishibashi and Yoshiyuki Morishita*
Affiliation:
- Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama,Japan
Keywords: Diuretics, cardiovascular disease, chronic kidney disease, spironolactone, mineralocorticoid receptor antagonist, dialysis.
Abstract: Cardiovascular disease is one of the most important risk factors for mortality and morbidity in patients with Chronic Kidney Disease (CKD). This systematic review focuses on the protective effects of diuretics against the development of cardiovascular disease in patients with CKD. Among various kinds of diuretics, spironolactone, a mineralocorticoid receptor antagonist, has been shown to have protective effects against cardiovascular disease in patients with all stages of CKD, including predialysis, hemodialysis, and peritoneal dialysis. Low-dose loop diuretics have also been shown to have cardioprotective effects in patients with CKD during the pre-dialysis and hemodialysis stages; however, high-dose loop diuretics have failed to show these cardioprotective effects. The protective effects of other classes of diuretics, including thiazide and tolvaptan, against cardiovascular diseases in patients with CKD remain unclear.
Export Options
About this article
Cite this article as:
Aomatsu Akinori , Ookawara Susumu , Ishibashi Kenichi and Morishita Yoshiyuki*, Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review, Cardiovascular & Hematological Agents in Medicinal Chemistry 2018; 16 (1) . https://dx.doi.org/10.2174/1871525716666180402145228
DOI https://dx.doi.org/10.2174/1871525716666180402145228 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.
Current Pharmaceutical Design Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Current Hot Potatoes in Atrial Fibrillation Ablation
Current Cardiology Reviews A Box-Behnken Optimized Methodology for the Quantification of Diclofenac using a Carbon Paste-Multiwalled Carbon Nanotubes Electrode
Current Analytical Chemistry A Hybrid Evolutionary System for Automated Artificial Neural Networks Generation and Simplification in Biomedical Applications
Current Bioinformatics Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design Analysis of Homocysteine in Plasma of Rats Exposed to High-fat Diet and Chronic Unpredictable Mild Stress by LC/ESI-MS/MS
Current Analytical Chemistry Asthma-COPD Overlap: A more Simplistic Approach
Current Respiratory Medicine Reviews Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Newer Advances in Cardiovascular Metabolism and Diagnostic Technologies)
Current Pharmaceutical Design Orekhov`s Method: Reassessment of In vitro Lipid Uptake Assays
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Role of the Endothelium in the Pathogenesis of Atherosclerosis and its Therapeutic Implications
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes
Current Drug Metabolism Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Editorial (Thematic Issue: What's Behind the Sex Gap in Cardiovascular Mortality?)
Current Pharmaceutical Design Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors
Current Pharmaceutical Design